Actinium Pharmaceuticals, Inc. – (ATNM)

Targeted Radiotherapies for
Patients with Unmet Needs

Actinium is developing a pipeline of Antibody Radiation Conjugates
for targeted conditioning and combination therapies

The Pivotal Phase 3 SIERRA Trial for Iomab-B is 100% Enrolled.

Featured Video

ACTINIUM PHARMACEUTICALS –
HARNESSING THE POWER OF
RADIATION

Email Signup

Receive the latest news, events and updates!

© 2022 Actinium Pharmaceuticals, Inc. All Rights Reserved.